Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00657202 · ClinicalTrials.gov registry record · Early Phase 1
Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1
A Early Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 11
- Enrollment target
NCT00657202: Completed Early Phase 1 study, sponsored by Massachusetts General Hospital.
NCT00657202 is a Early Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00657202, a Early Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine if ranibizumab can prevent the growth of neurofibromas. We will also be collecting extra blood and serum samples to help us learn more about NF1. Ranibizumab is a drug that affects the development of blood vessels that feed tumors. It targets a substance in the body called VEGF (Vascular Endothelial Growth Factor). VEGF helps tumors to grow and survive by supporting the growth of blood vessels that bring nutrients to the tumor. VEGF is made by cancerous tumors and also by non-cancerous tumors such as neurofibromas.
Interventions
- DRUG Ranibizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2008-03 |
| Est. Completion | 2013-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00657202
The ClinicalTrials.gov registry entry for NCT00657202 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ranibizumab is the first listed.
NCT00657202 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00657202 about?
NCT00657202 is a clinical study titled "Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1". The purpose of this research study is to determine if ranibizumab can prevent the growth of neurofibromas. We will also be collecting extra blood and serum samples to help us learn more about NF1. Ranibizumab is a drug that affects the development of blood vessels that feed tumors. It targets a subs...
What is the current status of trial NCT00657202?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 11 participants. The study started on 2008-03. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00657202?
The interventions under investigation include: Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT00657202?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.